Has IIT Bhubaneswar Signed an Agreement for a Novel TB Vaccine Technology?
Click to start listening
Synopsis
IIT Bhubaneswar, along with key partners, has signed a vital agreement to develop a groundbreaking TB vaccine, aiming to transition from lab research to commercial use. This collaborative effort highlights India's dedication to addressing significant public health challenges.
Key Takeaways
- IIT Bhubaneswar and partners have signed a vital agreement for TB vaccine research.
- The HSP Subunit Vaccine aims to enhance immunity against TB.
- Collaboration highlights India's strength in public health innovation.
- The agreement facilitates technology transfer and commercialization.
- TB remains a significant global health threat.
Bhubaneswar, Nov 24 (NationPress) In a significant move to enhance indigenous TB vaccine research, IIT Bhubaneswar, the Institute of Life Sciences (ILS), and the National Research Development Corporation (NRDC) have entered into a Quadripartite License Agreement with TechInvention Lifecare Limited.
This agreement facilitates the transfer of technology and the potential commercialization of a promising new vaccine candidate, the “HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis.”
The goal of this agreement is to transition the vaccine from laboratory research to product development, eventually leading to its commercial deployment.
According to the World Health Organization, TB took the lives of 1.23 million people in 2024, marking it as one of the deadliest infectious diseases globally.
Despite this, the world still depends on the Bacillus Calmette Guérin (BCG) vaccine, which was formulated over a century ago, offering only limited protection, particularly to infants, and is largely ineffective in preventing pulmonary TB in older populations.
“To meet this urgent and unmet need, the next-generation HSP Subunit Vaccine has been created through collaborative research led by Prof. Ashis Biswas of IIT Bhubaneswar and Dr. Sunil Kumar Raghav of ILS Bhubaneswar,” stated a press release from ILS.
This vaccine candidate is engineered to elicit strong humoral and cell-mediated immune responses while boosting the effectiveness of the existing BCG vaccine.
Recognizing its substantial public health significance, NRDC took the initiative to identify and assess this technology, streamlining the licensing process to ensure its progress.
“The HSP Subunit Vaccine candidate, collaboratively developed by the esteemed institutions ILS and IIT Bhubaneswar, signifies a major leap in India's battle against Mycobacterium tuberculosis. This partnership underscores the strength of India's research landscape and its commitment to tackling pressing public health issues,” ILS added.
TechInvention Lifecare Limited, the licensed industrial partner, will play a crucial role in transforming this indigenous vaccine technology into an effective public health solution.
Point of View
I believe that the recent agreement between IIT Bhubaneswar and its partners marks a pivotal moment in the fight against tuberculosis. Given the staggering number of lives lost to TB, this collaborative effort highlights India's commitment to innovation in public health. It’s essential that we continue to support and promote such initiatives that have the potential to save lives and reshape the future of healthcare.
NationPress
24/11/2025
Frequently Asked Questions
What is the HSP Subunit Vaccine?
The HSP Subunit Vaccine is a new vaccine candidate designed to combat Mycobacterium tuberculosis, aiming to provide enhanced protection compared to existing vaccines.
Who are the partners involved in this agreement?
The partners include IIT Bhubaneswar, the Institute of Life Sciences, the National Research Development Corporation, and TechInvention Lifecare Limited.
Why is this vaccine important?
This vaccine is crucial because tuberculosis is one of the deadliest infectious diseases, and current vaccines offer limited protection, particularly in older populations.
What does the agreement entail?
The agreement facilitates technology transfer and aims to advance the vaccine from laboratory research to commercial product development.
When was the agreement signed?
The agreement was formalized on November 24, 2024.
